Search
for
Sort by
Research 391–420 of 1000+
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- Ritlecitinib for the Management of Alopecia Areata: A Narrative Review of Real-World Evidence and Selected Post Hoc Analyses
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Abrocitinib Treatment in Diffuse Alopecia Areata: A Case Report and a Literature Review
- Alopecia areata treatment with baricitinib: different relapse phenotypes
- Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
- Baricitinib for the Treatment of Alopecia Areata
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- A Case of Alopecia Totalis with Lichen Planus Hypertrophicus Responded Excellently to Oral Tofacitinib-An Observation
- Drug-induced hair pigmentation: Clinical perspectives and updates
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
- The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- 1373 Expression of programmed cell death 1 inversely correlated with the density of CD8+ T cells infiltrating hair follicles in alopecia areata
- Baricitinib Attenuates IFN-γ and Polyinosinic:polycytidylic Acid‒Induced Mitochondrial Damage and Inflammasome Activation in Human Keratinocytes
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Alopecia Areata and Alopecia Areata Incognita
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores